Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
HIMS
Hims & Hers Health, Inc.
Peptide therapeutics manufacturing and development capabilities.
|
$8.19B |
$36.24
-2.61%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.06B |
$122.20
+0.61%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.58B |
$62.14
-1.91%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.57B |
$104.80
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$7.47B |
$112.53
-0.91%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$7.42B |
$63.45
+1.99%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.42B |
$118.69
-5.46%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$7.32B |
$96.84
-0.09%
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$7.30B |
$146.34
-1.23%
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$7.03B |
$243.09
-0.64%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$6.45B |
$21.28
+2.21%
|
|
GKOS
Glaukos Corporation
Glaukos markets ophthalmic drugs such as iDose TR and corneal health therapies (Photrexa, Epioxa), which are administered to treat eye conditions.
|
$6.41B |
$111.70
+2.59%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$6.21B |
$9.04
-1.04%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$6.13B |
$85.58
-4.57%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$6.06B |
$76.29
+0.86%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmic Drugs – direct development, licensing, and commercialization of eye-disease medications (e.g., MIEBO, XIIDRA).
|
$6.05B |
$17.07
+0.44%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.90B |
$94.82
-0.56%
|
|
PRAX
Praxis Precision Medicines, Inc.
Solidus platform develops antisense oligonucleotide (ASO) therapeutics (e.g., elsunersen).
|
$5.82B |
$277.20
+3.12%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$5.76B |
$44.36
-0.31%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.67B |
$119.27
+0.92%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.62B |
$40.21
-4.51%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.58B |
$220.02
-0.29%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$5.12B |
$56.24
-0.77%
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.98B |
$31.42
+0.22%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.86B |
$35.23
-0.93%
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$4.71B |
$19.73
-0.23%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$4.65B |
$28.19
-1.09%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$4.64B |
$49.31
-2.34%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.60B |
$27.28
+0.48%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.58B |
$76.97
-0.14%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.53B |
$26.00
-1.59%
|
|
LNTH
Lantheus Holdings, Inc.
Oncology-focused radiopharmaceutical assets and GRPR-targeted theranostics in the pipeline indicate an oncology biotech exposure.
|
$4.53B |
$66.62
|
Showing page 4 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
